Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?

IONS stock is down 6.36% at $54.40 as of the latest trade. The decline follows the announcement that the Phase 3 Lp(a)HORIZON trial of pelacarsen, a drug developed by Ionis and Novartis, missed its primary endpoint. This development triggered a cascade of price target reductions from multiple analysts, signaling reduced confidence in the drug's potential and the company's near-term prospects.

What Happened

Ionis Pharmaceuticals shares opened at $51.20, down 11.9% from the previous close, and have traded in a range of $50.56 to $54.66. The stock is currently at $54.40. The drop follows the announcement that the Lp(a)HORIZON trial of pelacarsen, a drug targeting cardiovascular disease, did not meet its primary endpoint. This outcome led to a series of price target reductions from analysts at H.C. Wainwright, Morgan Stanley, TD Cowen, Canaccord, and BMO Capital. H.C. Wainwright cut its price target to $100, while Canaccord reduced its target to $85. BMO Capital set its target at $54. These cuts reflect a reassessment of the drug's commercial potential and the company's overall valuation.

What The Data Shows

The stock has fallen 8.6% over the last eight sessions, from $63.24 to $57.80. Trading volume has been elevated at 1.6 million shares, which is 0.6 times the 3-month average. The stock has traded between $50.01 and $86.74 over the past 52 weeks. Recent insider transactions show 11 sales totaling $19.1 million and one purchase totaling $1.1 million. The most recent filing was on July 31, 2026. The company has a market cap of $9.7 billion and is unprofitable, with a trailing twelve-month net margin of -64.7% and revenue declining 7.4% year to date.

What To Watch

The next key event for the stock will be the company's upcoming earnings report. Investors should also monitor the breadth of analyst coverage and any new developments regarding the pelacarsen program or other pipeline assets.